FRONTEO and Astellas Pharma Sign Agreement on Target Molecule Discovery
NQ Score
30/100
N1 Content Completeness
3
AI Summary (NQ-processed)
AI company FRONTEO and Astellas Pharma have signed an agreement regarding target molecule discovery in drug creation. FRONTEO will provide its proprietary specialized AI, 'KIBIT,' to support Astellas Pharma's drug discovery research.